<table>
<thead>
<tr>
<th>PHARMACY POLICY STATEMENT</th>
<th>Ohio Medicaid</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DRUG NAME</strong></td>
<td>Supartz FX (sodium hyaluronate)</td>
</tr>
<tr>
<td><strong>BILLING CODE</strong></td>
<td>J7321</td>
</tr>
<tr>
<td><strong>BENEFIT TYPE</strong></td>
<td>Medical</td>
</tr>
<tr>
<td><strong>SITE OF SERVICE ALLOWED</strong></td>
<td>Office/Outpatient Hospital</td>
</tr>
<tr>
<td><strong>COVERAGE REQUIREMENTS</strong></td>
<td>Prior Authorization Required (Preferred Product)</td>
</tr>
<tr>
<td></td>
<td>Alternative preferred products include Gel-One, Gelsyn-3</td>
</tr>
<tr>
<td></td>
<td>QUANTITY LIMIT — 5 injections (5 units)</td>
</tr>
<tr>
<td><strong>LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY</strong></td>
<td>Click Here</td>
</tr>
</tbody>
</table>

Supartz FX (sodium hyaluronate) is a preferred product and will only be considered for coverage under the **medical** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

**OSTEOARTHRITIS OF THE KNEE**

For **initial** authorization:
1. Member must be 40 years old or older; AND
2. Member must have a diagnosis of osteoarthritis confirmed by radiological evidence (e.g. Kellgren-Lawrence Scale score of grade 2 or greater); AND
3. Medication must be prescribed by an orthopedic surgeon, interventional pain physicians, rheumatologists, physiatrists (PM&R) and all sports medicine subspecialties; AND
4. Member tried and failed an intra-articular corticosteroid injection(s) in which efficacy was < 4 weeks duration; AND
5. Documentation that member tried and failed ALL of the following:
   a) Weight loss attempts or attempts at lifestyle modifications to promote weight loss (only for members with BMI ≥30); AND
   b) Sufficient trial (e.g. 2 to 3 months) of non-pharmacologic therapies (bracing/orthotics, physical/occupational therapy); AND
   c) At least 3 simple analgesic therapies (acetaminophen, NSAIDs, oral or topical salicylates); AND
6. Member is not using medication for hip or shoulder related conditions; AND
7. Member is not allergic to avian proteins, feathers, and egg products.
8. **Dosage allowed:** Inject 20 mg (2 mL) once weekly for up to 5 weeks (total of 5 injections).

*If member meets all the requirements listed above, the medication will be approved for 6 months.*

For **reauthorization**:
1. Member must have documented significant pain relief that was achieved with the initial course of treatment; AND
2. Initial course of treatment has been completed for 6 months or longer; AND
3. Member meets all of the criteria for the initial approval.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*

CareSource considers Supartz FX (sodium hyaluronate) not medically necessary for the treatment of the following disease states based on a lack of
robust clinical controlled trials showing superior efficacy compared to currently available treatments:

- Refractory interstitial cystitis
- Arthropathy - Disorder of shoulder
- Intravitreal tamponade
- Keratoconjunctivitis sicca
- Subacromial impingement, Syndrome of the shoulder

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/17/2017</td>
<td>New policy for Supartz FX created. Minimum age and BMI requirements changed. Limits of additional courses of treatment changed.</td>
</tr>
</tbody>
</table>

References:


Effective date: 05/17/2017
Revised date: 05/17/2017